Tempus is a Chicago-based technology company founded in the year 2015. As the Center for analyzing clinical and molecular data, specialized doctors apply modern technology in treatment and fight against chronic diseases like cancer. Eric Lefkofsky is the co-founder and the CEO leading the company on a technological operating system for cancer immunotherapy research.
The company uses clinical data as a convenient method of learning trends in treating cancer and molecular data collection from patients under treatment. Lefkofsky has taken interest to partner other companies in achieving common goals in healthcare through machine learning, sequencing, and bioinformatics. Tempus, therefore, analyzes data sets for relevant patterns which helps identify the most likely active immunotherapies given to the cohort of patients.
Tempus work to reduce the number of cancer patients and eradicate chances of attack through its research programs. New and existing companies have boosted the Tempus in the realization of its goals by funding, in March 2018; the company received $80 million courtesy of New Investors Trust Co., Revolution Growth, and New Enterprise Associates to make sure that the company advances in cancer research.
The company embraces the new technology as its potential benefits go beyond risk identification and screening. With the increase in machine learning, doctors can provide treatment plans for cancer patients, matching patients with clinical trials, increasing therapy selections and cancer drug development.
Tempus constitute of research personnel who ensure availability and accessibility of cancer research programs. As a way of simplifying methodology used in medical research, laboratory firms adopt a standard consent form to ease data sharing between medical research centers. Lofkofsky also believes that when patients give their medical data records, it will help in collection and analysis of large volumes of data.
The primary challenge for medical researchers is that data sets lack volume and most often, they face restrictive legal terms and reluctant sharing partnerships. With the shared genomic data sets for medical research, the agreements set for private companies are generally different between institutions. Therefore, to enhance the accessibility of data operation in medical firms, Tempus should work more on platforms and standardization of terms.